Ravindra Kashyap, MD
Pulmonary Disease · Peoria, ILNPI 1437145273
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,625 of the $5,483 with a category attached, or 84.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.
Across 247 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$606
- Regeneron Healthcare Solutions, Inc.$521
- Boehringer Ingelheim$494
- Harmony Biosciences LLC$422
- Jazz Pharmaceuticals Inc.$386
- plus $2K from 25 others
Across 8 payments — averaging $5036.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$40K
What the payments were for
- Consulting fees$3256%
- Speaking & faculty fees$1002%
- Travel & lodging$1743%
- Food & beverage$4,62584%
- Education$2595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $1,175 |
| GSK | 21 | $606 |
| Regeneron Healthcare Solutions, Inc. | 12 | $521 |
| Boehringer Ingelheim | 22 | $494 |
| Harmony Biosciences LLC | 48 | $422 |
| Jazz Pharmaceuticals Inc. | 13 | $386 |
| Mylan Specialty L.p. | 14 | $229 |
| United Therapeutics Corporation | 6 | $184 |
| Sanofi | 9 | $171 |
| Amgen | 5 | $141 |
| Grifols USA, LLC | 7 | $140 |
| Insmed, Inc. | 6 | $131 |
| Philips North America LLC | 7 | $102 |
| Bayer | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Electromed, Inc. | 6 | $81 |
| Viatris Specialty LLC | 3 | $80 |
| Genentech USA, Inc. | 4 | $60 |
| Shire North American Group Inc | 4 | $55 |
| Intuitive Surgical | 1 | $51 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 3 | $47 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Verona Pharma, Inc. | 1 | $19 |
| Shionogi Inc | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,483 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 276 | $327,677 |
| Incruse ElliptaUmeclidinium Bromide | 109 | $77,614 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $72,439 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $43,001 |
| Ambrisentan | 14 | $39,900 |
| Spiriva RespimatTiotropium Bromide | 22 | $25,606 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $25,388 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $22,023 |
| Spiriva HandihalerTiotropium Bromide | 18 | $14,939 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $10,257 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 229 | $7,927 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,465 |
| Ventolin HfaAlbuterol Sulfate | 54 | $5,221 |
| Arnuity ElliptaFluticasone Furoate | 15 | $5,106 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $606 | $525,836552 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $494 | $47,62939 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,175 | $41,11065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Peoria
- Jon MichelPeoria$25K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.